MedTrace Logo

LAS41008 in Moderate to Severe Chronic Plaque Psoriasis

NCT01726933 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 839

Last updated 2015-12-02

No results posted yet for this study

Summary

The aim of the study is to evaluate the efficacy and safety of LAS41008 in comparison to active control and placebo in patients with moderate to severe chronic plaque psoriasis

Conditions

Interventions

DRUG

LAS41008

gastric resistant tablet, weekly up-titration up to maximal tolerated dosage

DRUG

LASW1835

gastric resistant tablet, weekly up-titration up to maximal tolerated dosage

DRUG

Placebo

gastric resistant tablet, weekly up-titration up to maximal tolerated dosage

Sponsors & Collaborators

  • Almirall Hermal GmbH

    collaborator INDUSTRY

  • Harrison Clinical Research

    collaborator INDUSTRY

  • Almirall, S.A.

    lead INDUSTRY

Principal Investigators

  • Ulrich Mrowietz, MD, Prof · University Medical Center, Schleswig-Holstein, Department of Dermatology, Schittenhelmstr. 7, 24105 Kiel, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2014-10-31
Completion
2015-11-30

Countries

  • Austria
  • Germany
  • Netherlands
  • Poland

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01726933 on ClinicalTrials.gov